Articles tagged "Alloantibodies"

2017 American Transplant Congress
Biomarkers of Epithelial-Mesenchymal Transition (EMT) in Chronic Allograft Nephropathy: Potential for Early Detection and Development of Novel Therapeutic Agents.
S. Kanangat, R. Miller, S. Rezaeian, H. Eldib, D. Cimbaluk, C. Fhied, I. Kurbegovic-Skaljic, M. Prod, J. Borgia, M. Flaws, D. Castillo, R. DeCresce.
Pathology, BioChemistry and Medical Laboratory Sciences, Rush University Medical Center, Chicago, IL
Purpose: To detect markers and novel treatment targets related to fibrogenesis and eventual graft loss by focusing on Epithelial Mesenchymal transition (EMT) which requires understanding…
2017 American Transplant Congress
Dual Targeting of Costimulation and Proteasome to Desensitize and Prolong Graft Survival of Sensitized Nonhuman Primates.
J. Kwun,¹ C. Burghuber,¹ M. Manook,¹ B. Ezekian,¹ J. Park,^1,2 K. Freishlag,¹ J. Yoon,¹ N. Iwakoshi,³ A. Farris,⁴ S. Knechtle.¹
¹Surgery, Duke Transplant Center, Durham, NC; ²Surgery, Samsung Medical Center, Seoul, Korea; ³Surgery, Emory Transplant Center, Atlanta, GA; ⁴Pathology, Emory University, Atlanta, GA
[Background] Pre-formed donor-specific anti-HLA antibodies (DSA) from prior transplantation, transfusion, or pregnancy affects a significant portion (35%) of patients awaiting a kidney transplant. Highly sensitized…
2017 American Transplant Congress
High Titer De Novo Donor-Specific HLA Alloantibodies and Cardiac Allograft Vasculopathy After Pediatric Heart Transplantation.
B. Das,¹ S. Zhang,² A. Gao,² C. Lacelle.³
¹Division of Cardiology, Dept. of Pediatrics, UTSW Medical Center, Dallas, TX; ²Department of Clinical Science Research, UTSW Medical Center, Dallas, TX; ³Department of Pathology, UTSW Medical Center, Dallas, TX
Background: Cardiac allograft vasculopathy (CAV) continues to be a limiting factor in long-term survival after pediatric heart transplantation (HT). Criteria for early diagnosis of CAV…
2017 American Transplant Congress
Factors Affecting Desensitization Outcome.
A. Zachary,¹ R. Montgomery,² M. Leffell.¹
¹Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; ²NYU Langone Transplant Institute, NYU University, New York, NY
The purpose of this study was to identify factors that affect the outcome of desensitization. We reviewed antibody and HLA mismatch data from 114 patients…
2017 American Transplant Congress
Accelerated De-Novo Donor-Specific Antibody-Mediated Rejection in a Non-Human Primate Model of Renal Transplantation.
J. Danobeitia, P. Chlebeck, J. Torrealba, T. Zens, L. Zitur, A. D'Alessandro, L. Fernandez.
Surgery - Division of Transplantation, University of Wisconsin-Madison, Madison, WI
The development of accelerated antibody-mediated rejection (ABMR) is associated with early allograft dysfunction and premature graft loss. In animals, pre-sensitization is usually required in order…
2017 American Transplant Congress
The Incremental of Cost of Incompatible Living Donor Kidney Transplant: A National Cohort Analysis.
D. Axelrod,¹ K. Lentine,² M. Schnitzler,² H. Xiao,² X. Lou,³ B. Orandi,³ J. Garonzik Wang,³ A. Massie,³ D. Segev.³
¹Surgery, East Carolina University, Greenville, NC; ²Transplant, Saint Louis University, St. Louis, MO; ³Surgery, Johns Hopkins University, Baltimore, MD
Incompatible living donor kidney transplant (ILDKT) has been established as an effective option for patients with willing but human leukocyte antigen incompatible live donors, reducing…
2017 American Transplant Congress
TACI Polymorphisms Associated with De Novo Alloantibodies in Humans and Allograft Rejection in Mice.
J. Platt,¹ E. Farkash,² A. Lefferts,¹ M. Samaniego,³ M. Cascalho.¹
¹Surgery, University of Michigan, Ann Arbor, MI; ²Pathology, University of Michigan, Ann Arbor, MI; ³Internal Medicine, University of Michigan, Ann Arbor, MI
A. Trans-membrane Activator and CAML Interactor (TACI) controls B cell differentiation and memory and exists as numerous allelic variants among healthy individuals and individuals with…
2017 American Transplant Congress
Rapid Depletion of Circulating DSA and Treatment of Acute Antibody-Mediated Rejection with the Combination of CTLA-4Ig/Belatacept and Bortezomib in Mouse and Man.
J. Young,¹ A. Vannier,¹ G. Bumgardner,² A. Chong,¹ R. Pelletier.²
¹Sugery, University of Chicago, Chicago, IL; ²Surgery, The Ohio State University, Columbus, OH
Antibody mediated rejection (AMR) is a major cause of rejection, and there are limited therapeutic options for reversing alloantibody production when it is fully established.…
2017 American Transplant Congress
Validation of a Novel Computational Approach for Predicting HLA Immunogenicity Based on Quantification of Structural and Surface Electrostatic Potential Differences Between Donor and Recipient HLA.
V. Kosmoliaptsis,¹ C. Kling,² M. Robb,³ D. Collett,³ J. Bradley,¹ C. Taylor,¹ D. Kabelitz,² D. Mallon.¹
¹Department of Surgery, University of Cambridge, Cambridge, United Kingdom; ²University of Kiel, Kiel, Germany; ³NHS Blood and Transplant, Bristol, United Kingdom
Background: Our preliminary work indicates that donor HLA immunogenicity in kidney and haematopoietic stem cell transplantation can be predicted by comparative assessment of donor and…
2017 American Transplant Congress
Effects of Tofacitinib (JAK-3 Inhibitor) on De Novo HLA-A2 Antibody Production in a Mouse Model of Allo-Sensitization.
N.-N. Chai, G. Wu, I. Kim, A. Klein, S. Jordan.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
Purpose: Tofacitinib is a Janus Kinase Inhibitor currently approved by FDA for treatment of rheumatoid arthritis. In considering its effect in reducing B cell proliferation…